TY - JOUR T1 - Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02341-2018 VL - 54 IS - 3 SP - 1802341 AU - Joseph Jacob AU - Brian J. Bartholmai AU - Coline H.M. van Moorsel AU - Srinivasan Rajagopalan AU - Anand Devaraj AU - Hendrik W. van Es AU - Teng Moua AU - Frouke T. van Beek AU - Ryan Clay AU - Marcel Veltkamp AU - Maria Kokosi AU - Angelo de Lauretis AU - Eoin P. Judge AU - Teresa M. Jacob AU - Tobias Peikert AU - Ronald Karwoski AU - Fabien Maldonado AU - Elisabetta Renzoni AU - Toby M. Maher AU - Andre Altmann AU - Athol U. Wells Y1 - 2019/09/01 UR - http://erj.ersjournals.com/content/54/3/1802341.abstract N2 - The advent of antifibrotic agents [1, 2] as standard of care in idiopathic pulmonary fibrosis (IPF) requires that new non-inferiority IPF drug trials will need to identify smaller declines of forced vital capacity (FVC). Marginal annualised FVC declines (between 5.00 and 9.99%) are particularly challenging to interpret as they might reflect measurement variation or genuine clinical deterioration [3]. Following on from previous baseline-only computed tomography (CT) analyses [4], the current study examined whether changes in computer features (CALIPER) across serial CT examinations could be considered as a trial co-endpoint, particularly with regard to adjudicating marginal FVC declines, and therefore improve the sensitivity of IPF drug trials.Change in the vessel-related structures, a computer-derived CT variable, is a strong predictor of outcome in idiopathic pulmonary fibrosis and can increase power in future drug trials when used as a co-endpoint alongside forced vital capacity change http://bit.ly/2M7DfKS ER -